← Alto Neuroscience, Inc. (ANRO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Alto Neuroscience, Inc. (ANRO)
Pharmaceutical Preparations · market cap $1.1B · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
14
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Alto Neuroscience (ANRO) is a clinical-stage pharmaceutical company focused primarily on CNS disorders, with a pipeline spanning Major Depressive Disorder, Bipolar Depression, Treatment-Resistant Depression, and Schizophrenia. The company trades at ~$25.90 with a $909M market cap, ~$264M in cash (roughly 29 months of runway), and two near-term Phase 2 readouts — ALTO-100 in Bipolar Depression (est. August 15, 2026) and ALTO-300 in MDD (est. December 15, 2026) — acting as primary catalysts.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 2 · ALTO-300imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| GB001 recombinant peptide spray low dose group、high dose group | Phase 2 | Healthy |
| ALTO-100 | Phase 2 | Bipolar Disorder I or II With a Major Depressive Episode |
| ALTO-300 oral (PO) tablet | Phase 2 | Major Depressive Disorder |
| ALTO-100 PO tablet | Phase 2 | Major Depressive Disorder |
| ALTO-300 PO Tablet | Phase 2 | Major Depressive Disorder |
| ALTO-300 | Phase 2 | Major Depressive Disorder |
| ALTO-203 25 μg | Phase 2 | Major Depressive Disorder |
| ALTO-101 | Phase 2 | Schizophrenia |
| PA9159 Metered-Dose Inhaler, 60 μg per day for 28 days | Phase 2 | Bronchial Asthma |
| PA1010 | Phase 2 | Chronic HBV Infection |
| PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days | Phase 2 | Bronchial Asthma |
| PA9159 nasal spray solution, 10 μg once daily for 14 days | Phase 2 | Allergic Rhinitis |
| XKH004 | Phase 3 | Phase III |
| ALTO-207 | Phase 2 | Treatment-resistant Depression (TRD) |
Price & technical context
3-month
+2.1%
6-month
+8.1%
12-month
+529.6%
52-wk range
$4.07–$36.64
vs 50-day MA
-18.2%
vs 200-day MA
+6.9%
Realized vol
109.0%
Max drawdown
-87.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ANRO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 14 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.